HUTCHMED’s Cancer Drug Fast-Tracked in China

HUTCHMED (HCM) has released an update.

HUTCHMED has announced that China’s NMPA has accepted and granted Priority Review for the New Drug Application of tazemetostat, a novel treatment for relapsed or refractory follicular lymphoma. Already approved in the U.S. and Japan, tazemetostat’s China NDA is backed by promising results from a Phase II study. This development marks a significant step in HUTCHMED’s strategic collaboration with Epizyme for the drug’s research, development, and potential commercialization in Greater China.

For further insights into HCM stock, check out TipRanks’ Stock Analysis page.